| . | Study population (n = 245) . |
|---|---|
| Clinical features | |
| Male sex, n (%) | 145 (59) |
| Age, median (25th–75th) | 38 (29–49) |
| Children (<16 years), n (%) | 14 (5.7) |
| Family history of SCD, n (%) | 26 (11) |
| Previous AF, n (%) | 37 (15) |
| Hypertension, n (%) | 50 (20) |
| Current smokers, n (%) | 42 (17) |
| Dyslipidaemia, n (%) | 19 (8) |
| Diabetes, n (%) | 6 (2.5) |
| EF (%), median (25th–75th) | 60 (55–65) |
| Previous syncope, n (%) | 50 (20) |
| ECG features at hospital admission, median (25th–75th) | |
| HR (b.p.m.) | 73 (65–85) |
| PR (ms) | 170 (150–184) |
| QRS (ms) | 91 (85–100) |
| QTc (ms) | 412 (400–439) |
| VF circumstances, n (%) | |
| At rest | 161 (66) |
| During effort | 60 (24) |
| During sleep | 24 (10) |
| Diagnostic work-up, n (%) | |
| Complete work-up | 113 (46) |
| Coronary angiogram | 220 (90) |
| Cardiac CT scan | 25 (10) |
| CMR | 160 (65) |
| Sodium-channel blocker test | 156 (64) |
| Exercise stress test | 195 (80) |
| EPS | 144 (59) |
| VA inducibility | 50 (35) |
| Type of induced arrhythmias, n (%) | |
| Monomorphic VT | 2 (4) |
| Polymorphic VT | 7 (14) |
| VF | 41 (82) |
| Genetic test | 44 (18) |
| Myocardial biopsy | 4 (1.6) |
| Therapeutic management, n (%) | |
| ICD implantation | 226 (92) |
| Dual-chamber ICD | 66 (29) |
| Single-chamber ICD | 146 (65) |
| Subcutaneous ICD | 14 (6) |
| Drug therapy only | 18 (8) |
| . | Study population (n = 245) . |
|---|---|
| Clinical features | |
| Male sex, n (%) | 145 (59) |
| Age, median (25th–75th) | 38 (29–49) |
| Children (<16 years), n (%) | 14 (5.7) |
| Family history of SCD, n (%) | 26 (11) |
| Previous AF, n (%) | 37 (15) |
| Hypertension, n (%) | 50 (20) |
| Current smokers, n (%) | 42 (17) |
| Dyslipidaemia, n (%) | 19 (8) |
| Diabetes, n (%) | 6 (2.5) |
| EF (%), median (25th–75th) | 60 (55–65) |
| Previous syncope, n (%) | 50 (20) |
| ECG features at hospital admission, median (25th–75th) | |
| HR (b.p.m.) | 73 (65–85) |
| PR (ms) | 170 (150–184) |
| QRS (ms) | 91 (85–100) |
| QTc (ms) | 412 (400–439) |
| VF circumstances, n (%) | |
| At rest | 161 (66) |
| During effort | 60 (24) |
| During sleep | 24 (10) |
| Diagnostic work-up, n (%) | |
| Complete work-up | 113 (46) |
| Coronary angiogram | 220 (90) |
| Cardiac CT scan | 25 (10) |
| CMR | 160 (65) |
| Sodium-channel blocker test | 156 (64) |
| Exercise stress test | 195 (80) |
| EPS | 144 (59) |
| VA inducibility | 50 (35) |
| Type of induced arrhythmias, n (%) | |
| Monomorphic VT | 2 (4) |
| Polymorphic VT | 7 (14) |
| VF | 41 (82) |
| Genetic test | 44 (18) |
| Myocardial biopsy | 4 (1.6) |
| Therapeutic management, n (%) | |
| ICD implantation | 226 (92) |
| Dual-chamber ICD | 66 (29) |
| Single-chamber ICD | 146 (65) |
| Subcutaneous ICD | 14 (6) |
| Drug therapy only | 18 (8) |
AF, atrial fibrillation; CMR, cardiac magnetic resonance; CT, computed tomography; EF, ejection fraction; EPS, electrophysiologic study; HR, heart rate; ICD, implantable cardioverter-defibrillator; SCD, sudden cardiac death; VA, ventricular arrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia.
| . | Study population (n = 245) . |
|---|---|
| Clinical features | |
| Male sex, n (%) | 145 (59) |
| Age, median (25th–75th) | 38 (29–49) |
| Children (<16 years), n (%) | 14 (5.7) |
| Family history of SCD, n (%) | 26 (11) |
| Previous AF, n (%) | 37 (15) |
| Hypertension, n (%) | 50 (20) |
| Current smokers, n (%) | 42 (17) |
| Dyslipidaemia, n (%) | 19 (8) |
| Diabetes, n (%) | 6 (2.5) |
| EF (%), median (25th–75th) | 60 (55–65) |
| Previous syncope, n (%) | 50 (20) |
| ECG features at hospital admission, median (25th–75th) | |
| HR (b.p.m.) | 73 (65–85) |
| PR (ms) | 170 (150–184) |
| QRS (ms) | 91 (85–100) |
| QTc (ms) | 412 (400–439) |
| VF circumstances, n (%) | |
| At rest | 161 (66) |
| During effort | 60 (24) |
| During sleep | 24 (10) |
| Diagnostic work-up, n (%) | |
| Complete work-up | 113 (46) |
| Coronary angiogram | 220 (90) |
| Cardiac CT scan | 25 (10) |
| CMR | 160 (65) |
| Sodium-channel blocker test | 156 (64) |
| Exercise stress test | 195 (80) |
| EPS | 144 (59) |
| VA inducibility | 50 (35) |
| Type of induced arrhythmias, n (%) | |
| Monomorphic VT | 2 (4) |
| Polymorphic VT | 7 (14) |
| VF | 41 (82) |
| Genetic test | 44 (18) |
| Myocardial biopsy | 4 (1.6) |
| Therapeutic management, n (%) | |
| ICD implantation | 226 (92) |
| Dual-chamber ICD | 66 (29) |
| Single-chamber ICD | 146 (65) |
| Subcutaneous ICD | 14 (6) |
| Drug therapy only | 18 (8) |
| . | Study population (n = 245) . |
|---|---|
| Clinical features | |
| Male sex, n (%) | 145 (59) |
| Age, median (25th–75th) | 38 (29–49) |
| Children (<16 years), n (%) | 14 (5.7) |
| Family history of SCD, n (%) | 26 (11) |
| Previous AF, n (%) | 37 (15) |
| Hypertension, n (%) | 50 (20) |
| Current smokers, n (%) | 42 (17) |
| Dyslipidaemia, n (%) | 19 (8) |
| Diabetes, n (%) | 6 (2.5) |
| EF (%), median (25th–75th) | 60 (55–65) |
| Previous syncope, n (%) | 50 (20) |
| ECG features at hospital admission, median (25th–75th) | |
| HR (b.p.m.) | 73 (65–85) |
| PR (ms) | 170 (150–184) |
| QRS (ms) | 91 (85–100) |
| QTc (ms) | 412 (400–439) |
| VF circumstances, n (%) | |
| At rest | 161 (66) |
| During effort | 60 (24) |
| During sleep | 24 (10) |
| Diagnostic work-up, n (%) | |
| Complete work-up | 113 (46) |
| Coronary angiogram | 220 (90) |
| Cardiac CT scan | 25 (10) |
| CMR | 160 (65) |
| Sodium-channel blocker test | 156 (64) |
| Exercise stress test | 195 (80) |
| EPS | 144 (59) |
| VA inducibility | 50 (35) |
| Type of induced arrhythmias, n (%) | |
| Monomorphic VT | 2 (4) |
| Polymorphic VT | 7 (14) |
| VF | 41 (82) |
| Genetic test | 44 (18) |
| Myocardial biopsy | 4 (1.6) |
| Therapeutic management, n (%) | |
| ICD implantation | 226 (92) |
| Dual-chamber ICD | 66 (29) |
| Single-chamber ICD | 146 (65) |
| Subcutaneous ICD | 14 (6) |
| Drug therapy only | 18 (8) |
AF, atrial fibrillation; CMR, cardiac magnetic resonance; CT, computed tomography; EF, ejection fraction; EPS, electrophysiologic study; HR, heart rate; ICD, implantable cardioverter-defibrillator; SCD, sudden cardiac death; VA, ventricular arrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
